Quarterly ResultAug 13, 2026, 04:25 PM
Rani Therapeutics H1 Net Loss $(16.4)M; Revenue $3.4M; Cash $53.4M
AI Summary
Rani Therapeutics Holdings, Inc. reported a net loss of $16.4 million for the six months ended June 30, 2026, a reduction from $24.0 million in the prior year period. Contract revenue saw a substantial increase to $3.4 million. The company concluded the period with $53.4 million in cash, cash equivalents, and marketable securities, which is projected to cover operations for at least the next twelve months. Despite reduced operating expenses, net cash used in operating activities increased, and the company anticipates continued losses and a need for future financing.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $(16.4) million, an improvement from $(24.0) million YoY.
- Contract revenue for the six months ended June 30, 2026, increased significantly to $3.4 million from $0.2 million YoY.
- Cash, cash equivalents, and marketable securities totaled $53.4 million as of June 30, 2026.
- The company expects its current liquidity to fund operations for at least 12 months.
- Net cash used in operating activities increased to $(15.5) million for the six months, compared to $(13.9) million YoY.
- Total operating expenses decreased to $20.6 million for the six months from $22.7 million in the prior year period.
- Rani Therapeutics raised $18.7 million from the issuance of common stock and pre-funded warrants in May 2026.
- Net loss per Class A common share improved to $(0.08) for the six months from $(0.40) YoY.
Price Impact
More from RANI